Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
- Daten zur Untersuchung der PSA-Progression mit Enzalutamid oder Placebo, gemeinsam mit anderen Abstracts veröffentlicht, liefern weitere Belege für die Vorteile von Enzalutamid im Rahmen...
- Les données examinant la progression du PSA avec soit l’enzalutamide soit un placebo, présentées conjointement avec d’autres extraits, enrichissent les éléments de preuve montrant les...
- Data examining PSA progression with either enzalutamide or placebo presented alongside other abstracts, increase the body of evidence showing the benefits of enzalutamide for men living...
Tender offer for all of the outstanding shares of Medivation common stock expired as scheduled one minute after 11:59 p.m., Eastern time, on September 27, 2016 Pfizer and Medivation...
Transaction expected to close in the Third-Quarter 2016 Pfizer Inc. (NYSE: PFE) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976...
Faruqi & Faruqi, LLP Announces Filing of a Class Action Lawsuit Against Medivation, Inc. PR Newswire NEW YORK, Sept. 9, 2016 NEW YORK, Sept. 9, 2016 /PRNewswire/ -- Notice is hereby given...
MEDIVATION SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Medivation, Inc. (MDVN) Over the Proposed Sale of the Company to Pfizer Inc. PR Newswire NEW YORK, Sept. 6...
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Medivation, Inc. ("Medivation” or "the Company") (Nasdaq: MDVN...
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by...
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Medivation, Inc. (“Medivation”) (NASDAQ:MDVN) stock prior to August 22...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
